Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorHEMAR, Victor
dc.contributor.authorRIVIERE, Etienne
dc.contributor.authorGREIB, Carine
dc.contributor.authorMACHELART, Irene
dc.contributor.authorROUCOULES, Manon
dc.contributor.authorPROT, Camille
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPELLEGRIN, Jean-Luc
dc.contributor.authorVIALLARD, Jean Francois
dc.contributor.authorLAZARO, Estibaliz
dc.date.accessioned2022-01-18T13:25:47Z
dc.date.available2022-01-18T13:25:47Z
dc.date.issued2021-12
dc.identifier.issn1750-7448 (Electronic) 1750-743X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124421
dc.description.abstractEnAim: To describe the effects of a summertime pause (SP) in immunoglobulin replacement therapy (IgRT). Patients & methods: We conducted a prospective single-center observational study, including 44 patients undergoing intravenous IgRT between May and June 2019 in a French teaching hospital. Results: IgRT was interrupted in 23 patients from June to October. Patients who underwent an SP were older, more likely to have secondary immunodeficiency (SID) and received lower doses of immunoglobulin and more antibiotics during winter. Most patients who did not undergo an SP had severe primary immunodeficiency. The SP did not increase the risk of infection, improved the quality of life and reduced treatment costs. Conclusion: SP in IgRT is a safe practice and should be considered for patients with mild SID. Lay abstract Immunoglobulin replacement therapy (IgRT) is an expensive treatment used to prevent infections in patients with immunodeficiency. Becauase most of the infections occur during winter, it is sometimes possible to interrupt IgRT during summer. In our study between May and October 2019, the 23 patients who underwent a summertime pause (SP) did not have more infections than the 21 who did not; the former also described an improvement in their quality of life. However, the physicians proposed SP to patients with a specific type of immunodeficiency, with fewer infections during winter and lower doses of IgRT. We report here for the first time the safety and benefits of a summertime pause in IgRT, for selected patients with less severe immunodeficiency. eng
dc.language.isoENen_US
dc.subject.enCommon variable immunodeficiency infection control
dc.subject.enHematological malignancy
dc.subject.enIntravenous immunoglobulin
dc.subject.enPrimary immunodeficiency
dc.subject.enQuality of life
dc.subject.enReplacement therapy
dc.subject.enSecondary immunodeficiency
dc.subject.enSummertime pause
dc.subject.enTreatment satisfaction
dc.title.enA summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis
dc.typeArticle de revueen_US
dc.identifier.doi10.2217/imt-2020-0313en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34743547en_US
bordeaux.journalImmunotherapyen_US
bordeaux.page1491-1499en_US
bordeaux.volume13en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue18en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamMORPH3Eusen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03532274
hal.version1
hal.date.transferred2022-01-18T13:25:50Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Immunotherapy&rft.date=2021-12&rft.volume=13&rft.issue=18&rft.spage=1491-1499&rft.epage=1491-1499&rft.eissn=1750-7448%20(Electronic)%201750-743X%20(Linking)&rft.issn=1750-7448%20(Electronic)%201750-743X%20(Linking)&rft.au=HEMAR,%20Victor&RIVIERE,%20Etienne&GREIB,%20Carine&MACHELART,%20Irene&ROUCOULES,%20Manon&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée